sitagliptin + metformin (Genix Pharma)

Gvia-M is a branded generic combination of **sitagliptin** and **metformin hydrochloride**, developed and marketed by **Genix Pharma**. It is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to lower high blood sugar by increasing the levels of active incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Metformin is a biguanide that reduces the amount of glucose produced by the liver and improves the body's response to insulin. The combination provides complementary mechanisms of action to manage blood glucose levels more effectively than either agent alone.

Brand names

Gvia-M

Other names

Sitagliptin/Metformin